N. Regamey (Bern, Switzerland), N. Simmonds (London, United Kingdom)
Lung function decline in a modern cystic fibrosis cohort
L. Welsh, L. King, P. Robinson, C. Robertson, S. Ranganathan (Melbourne, Australia)
|   |
Is lung function worsening during adolescence in cystic fibrosis? A retrospective study
S. Volpi, A. Marostica, C. D‘Orazio, G. Amenta, E. Pintani, B. Assael (Verona, Italy)
| |
Comparative study of three quality of life instruments in adolescent and adults with cystic fibrosis
M. Cebrian, J. Ferrero, E. Ansotegui, A. Sole (Valencia, Spain)
| |
Comparison of the Cystic Fibrosis Questionnaire with the St George‘s Respiratory Questionnaire in adult patients with cystic fibrosis
M. Hofer, A. Hirt, T. Kurowski, A. Boehler (Zurich, Switzerland)
| |
Survival at low lung function in cystic fibrosis: Cohort study from 1995 to 2010
M. Osman, T. Daniels (Southampton, United Kingdom)
| |
The use of high frequency chest wall oscillation during an acute infective pulmonary exacerbation of cystic fibrosis
A. Banks, G. Davies, P. Agent, L. Osman, D. Bilton, M. Hodson (London, United Kingdom)
| |
Long inhalation time is associated with short treatment time when using the I-neb AAD system in target inhalation mode
T. Spencer, A. Black, N. Smith, K. Nikander, T. Dyche (Chichester, Portsmouth, United Kingdom; Parsippany, United States Of America)
| |
Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection
H. Mazurek, R. Chiron, G. Varoli, D. Santoro, H. Cicirello, Y. Antipkin (Rabka-Zdroj, Poland; Montpelier, France; Parma, Italy; Rockville, United States Of America; Kyiv, Ukraine)
| |
Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection
M. Govoni, G. Poli, H. Cicirello, D. Santoro, D. Acerbi, J. Ruzicka (Parma, Italy; Rockville, United States Of America; Bratislava, Slovakia)
| |
Long-term linezolid in cystic fibrosis patients chronically colonized with Staphylococcus aureus (SA)
A. Sole, M. Cebrian, E. Ansótegui, E. Monte, E. Sanmartín, J.L. Perez (Valencia, Spain)
| |
Allergic bronchopulmonary aspergillosis (ABPA) prevalence in adult cystic fibrosis (CF) patients. Usefulness of recombinant Aspergillus fumigatus IgE (rAsp f) in diagnosis and monitoring treatment
C. Navarro, M. Perez, D. Hernandez, E. Ansotegui, M. Cebrian, J. Peman, A. Sole (Valencia, Spain)
| |
Prevalence of tracheobronchomalacia in young children with cystic fibrosis
S. Poreddy, A. Withers, D. Cox, S. Stick (Subiaco, Australia)
| |
Oral health and some risk factors in children with cystic fibrosis
S. Mete, Y. Gokdemir, S. Peker, B. Karadag, B. Kargul (Istanbul, Turkey)
| |
Active and passive smoking by CF patients in Belgium: A national survey
V. Godding, L. Stevens, P. Lebecque, L. Galanti (Bruxelles, Yvoir, Belgium)
| |
Comparison of nanoduct versus macroduct sweat test for the diagnosis of cystic fibrosis in the newborn screening programme in Switzerland
J. Barben, C.S. Rueegg, S. Gallati, C.E. Kuehni, M. Baumgartner, T. Torresani, M.H. Schoeni, the Swiss CF Screening Group (St. Gallen, , Zurich, Switzerland)
| |